Characterization of antibody-mediated inhibition of natural killer (NK) cytotoxicity: evidence for blocking of both recognition and lethal hit stages of cytolysis. 1983

R Kahle, and J Hiserodt, and B Bonavida

Rat antisera prepared against murine, periodate-activated alloimmune cytotoxic lymphocytes (termed RAT) have previously been shown to effectively block T-cell-mediated cytotoxicity (CMC) at the "lethal hit" stage of cytolysis (J.C. Hiserodt and B. Bonavida, J. Immunol. 126, 256, 1981). Both natural killer (NK) and cytotoxic T lymphocytes (CTL) have been shown to mediate lysis by the same pathway, namely binding of effector to target cells, programming for lysis, and killer cell-independent target cell lysis. This result suggested that the molecular mechanism of NKCMC and CTLCMC may also be similar. In this context, RAT-mediated blocking of CTL was examined for its ability to block NKCMC. The results show that (1) addition of RAT serum or IgG fractions blocked NKCMC in the absence of complement in a 4-hr 51CR-release assay, and blocking was directed at the effector cell; (2) at the single-cell level, RAT serum blocked the formation of conjugates between effector and target cells; (3) in a Ca2+-pulse experiment, in which the effectors and targets were first allowed to bind in the absence of Ca2+ for 1 hr at 37 degrees C, followed by the addition of Ca2+ to initiate the lytic event, RAT was capable of blocking cytotoxicity after conjugate formation at the Ca2+-dependent lethal hit stage of cytolysis. The similarity of results in RAT blocking experiments of both the CTL and NK systems suggests a common molecular mechanism of cytolysis.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012515 Mast-Cell Sarcoma A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow. Mastocytoma, Malignant,Sarcoma, Mast-Cell,Malignant Mastocytoma,Malignant Mastocytomas,Mast Cell Sarcoma,Mast-Cell Sarcomas,Mastocytomas, Malignant,Sarcoma, Mast Cell,Sarcomas, Mast-Cell
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

R Kahle, and J Hiserodt, and B Bonavida
November 1974, European journal of immunology,
R Kahle, and J Hiserodt, and B Bonavida
September 1984, Journal of immunology (Baltimore, Md. : 1950),
R Kahle, and J Hiserodt, and B Bonavida
January 1993, Microbiology and immunology,
R Kahle, and J Hiserodt, and B Bonavida
January 1982, Advances in experimental medicine and biology,
R Kahle, and J Hiserodt, and B Bonavida
March 1982, Journal of immunology (Baltimore, Md. : 1950),
R Kahle, and J Hiserodt, and B Bonavida
January 2022, Current pharmaceutical biotechnology,
R Kahle, and J Hiserodt, and B Bonavida
May 2000, Immunology today,
R Kahle, and J Hiserodt, and B Bonavida
July 1989, Cancer,
Copied contents to your clipboard!